Next Meetings

March 2, 2018 10am-4pm PT

Preservation Park (Nile Hall)
1233 Preservation Park Way
Oakland CA, 94612

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.

Register or Register for the Live Webcast

Hemophilia A

New England CEPAC
March 29, 2018 10am-4pm EST

Boston Marriott Cambridge
50 Broadway
Cambridge, MA, 02142

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.

Register or Register for the Live Webcast

Cystic Fibrosis

Midwest CEPAC
May 17, 2018 10am-4pm CT

Midwest TBD

The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.


June 14, 2018 10am - 4pm PT

CTAF will convene to review ICER's report on CGRP inhibitors for prevention of migraine headaches.


Psoriasis Condition Update

New England CEPAC
July 12, 2018 10am - 4pm ET

TBD

The New England CEPAC will convene to review ICER's condition update on therapies for plaque psoriasis. During this meeting, the Council will also review a report on elagolix for endometriosis.


Endometriosis

New England CEPAC
July 12, 2018 10am - 4pm ET

TBD

The New England CEPAC will review ICER's report on elagolix for endometriosis.


Amyloidosis

Midwest CEPAC
September 13, 2018 10am- 4pm CT

TBD

The Midwest CEPAC will deliberate and vote on ICER's report on threatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council will also review a report on therapies for prostate cancer during this meeting.


Prostate Cancer

Midwest CEPAC
September 13, 2018 10am-4pm CT

TBD

The Midwest CEPAC will deliberate and vote on evidence presented in ICER's report on anti-androgen drugs for high risk prostate cancer. During this meeting, the Council will also discuss ICER's review of treatments for amyloidosis .


past Meetings

May 2017
ICER

Orphan Drug Assessment and Pricing Summit

ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.